Skip to main content
Mark Wallace, MD, Infectious Disease, Anacortes, WA

Mark Wallace MD FACP,FIDSA


Physician

Join to View Full Profile
  • 8630 Turners Bay PlaceAnacortes, WA 98221

  • Phone+1 407-920-3838

Dr. Wallace is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Naval Medical Center (San Diego)
    Naval Medical Center (San Diego)Fellowship, Infectious Disease, 1987 - 1989
  • University of Washington
    University of WashingtonResidency, Internal Medicine, 1982 - 1984
  • University of Vermont Medical Center
    University of Vermont Medical CenterInternship, Internal Medicine, 1981 - 1982
  • Saint Louis University School of Medicine
    Saint Louis University School of MedicineClass of 1981

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 1983 - 2026
  • FL State Medical License
    FL State Medical License 2005 - 2018
  • CA State Medical License
    CA State Medical License 1985 - 2007
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

  • Jay Sanford Award Armed Forces ID Society, 2011

Publications & Presentations

PubMed

Press Mentions

  • Travecta Therapeutics Appoints Leading Experts to Expand Its Scientific Advisory Leadership Team
    Travecta Therapeutics Appoints Leading Experts to Expand Its Scientific Advisory Leadership TeamFebruary 15th, 2022
  • CORBEVAX®, a COVID19 Vaccine Developed by Bio E-india Based on the RBD Protein Antigen Technology from Texas Children's Hospital Center for Vaccine Development, Receives World Health Organization Emergency Use Listing Approval
    CORBEVAX®, a COVID19 Vaccine Developed by Bio E-india Based on the RBD Protein Antigen Technology from Texas Children's Hospital Center for Vaccine Development, Receives World Health Organization Emergency Use Listing ApprovalJanuary 23rd, 2024

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: